Guillaume Kugener
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guillaume Kugener has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Neekesh V. Dharia
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
55 shared publications - Kimberly Stegmaier
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
44 shared publications - Joshua M. Dempster
Broad Institute of MIT and Harvard, Cambridge, USA
43 shared publications - Francisca Vazquez
Broad Institute of MIT and Harvard, Cambridge, USA
30 shared publications - Todd R. Golub
Broad Institute 24 Camridge, MA
30 shared publications - Amy Saur Conway
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
29 shared publications
Latest Publications
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Supplementary Tables from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Supplementary Tables from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Supplementary Figures from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Supplementary Figures from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Supplementary Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Supplementary Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
CRISPR–Cas9-based genetic screens have successfully identified cell type–dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have been performed in vitro using established cell lines, evaluating the physiologic relevance of these targets is critical. We have established a CRISPR screening approach using orthotopic xenograft models to validate and prioritize AML-enriched dependencies in vivo, including in CRISPR-competent AML patient-derived xenograft (PDX) models tractable for genome editing. Our integrated pipeline has revealed several targets with translational value, including SLC5A3 as a metabolic vulnerability for AML addicted to exogenous myo-inositol and MARCH5 as a critical guardian to prevent apoptosis in AML. MARCH5 repression enhanced the efficacy of BCL2 inhibitors such as venetoclax, further highlighting the clinical potential of targeting MARCH5 in AML. Our study provides a valuable strategy for discovery and prioritization of new candidate AML therapeutic targets.Significance:There is an unmet need to improve the clinical outcome of AML. We developed an integrated in vivo screening approach to prioritize and validate AML dependencies with high translational potential. We identified SLC5A3 as a metabolic vulnerability and MARCH5 as a critical apoptosis regulator in AML, both of which represent novel therapeutic opportunities.This article is highlighted in the In This Issue feature, p. 275
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
CRISPR–Cas9-based genetic screens have successfully identified cell type–dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have been performed in vitro using established cell lines, evaluating the physiologic relevance of these targets is critical. We have established a CRISPR screening approach using orthotopic xenograft models to validate and prioritize AML-enriched dependencies in vivo, including in CRISPR-competent AML patient-derived xenograft (PDX) models tractable for genome editing. Our integrated pipeline has revealed several targets with translational value, including SLC5A3 as a metabolic vulnerability for AML addicted to exogenous myo-inositol and MARCH5 as a critical guardian to prevent apoptosis in AML. MARCH5 repression enhanced the efficacy of BCL2 inhibitors such as venetoclax, further highlighting the clinical potential of targeting MARCH5 in AML. Our study provides a valuable strategy for discovery and prioritization of new candidate AML therapeutic targets.Significance:There is an unmet need to improve the clinical outcome of AML. We developed an integrated in vivo screening approach to prioritize and validate AML dependencies with high translational potential. We identified SLC5A3 as a metabolic vulnerability and MARCH5 as a critical apoptosis regulator in AML, both of which represent novel therapeutic opportunities.This article is highlighted in the In This Issue feature, p. 275
- 1 September 2023
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 25 (6) , e330-e337
Pilot Analysis of Surgeon Instrument Utilization Signatures Based on Shannon Entropy and Deep Learning for Surgeon Performance Assessment in a Cadaveric Carotid Artery Injury Control Simulation
BACKGROUND AND OBJECTIVES: Assessment and feedback are critical to surgical education, but direct observational feedback by experts is rarely provided because of time constraints and is typically only qualitative. Automated, video-based, quantitative feedback on surgical performance could address this gap, improving surgical training. The authors aim to demonstrate the ability of Shannon entropy (ShEn), an information theory metric that quantifies series diversity, to predict surgical performance using instrument detections generated through deep learning. METHODS: Annotated images from a publicly available video data set of surgeons managing endoscopic endonasal carotid artery lacerations in a perfused cadaveric simulator were collected. A deep learning model was implemented to detect surgical instruments across video frames. ShEn score for the instrument sequence was calculated from each surgical trial. Logistic regression using ShEn was used to predict hemorrhage control success. RESULTS: ShEn scores and instrument usage patterns differed between successful and unsuccessful trials (ShEn: 0.452 vs 0.370, P < .001). Unsuccessful hemorrhage control trials displayed lower entropy and less varied instrument use patterns. By contrast, successful trials demonstrated higher entropy with more diverse instrument usage and consistent progression in instrument utilization. A logistic regression model using ShEn scores (78% accuracy and 97% average precision) was at least as accurate as surgeons' attending/resident status and years of experience for predicting trial success and had similar accuracy as expert human observers. CONCLUSION: ShEn score offers a summative signal about surgeon performance and predicted success at controlling carotid hemorrhage in a simulated cadaveric setting. Future efforts to generalize ShEn to additional surgical scenarios can further validate this metric.
- 1 September 2023
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 25 (6) , e330-e337
Pilot Analysis of Surgeon Instrument Utilization Signatures Based on Shannon Entropy and Deep Learning for Surgeon Performance Assessment in a Cadaveric Carotid Artery Injury Control Simulation
BACKGROUND AND OBJECTIVES: Assessment and feedback are critical to surgical education, but direct observational feedback by experts is rarely provided because of time constraints and is typically only qualitative. Automated, video-based, quantitative feedback on surgical performance could address this gap, improving surgical training. The authors aim to demonstrate the ability of Shannon entropy (ShEn), an information theory metric that quantifies series diversity, to predict surgical performance using instrument detections generated through deep learning. METHODS: Annotated images from a publicly available video data set of surgeons managing endoscopic endonasal carotid artery lacerations in a perfused cadaveric simulator were collected. A deep learning model was implemented to detect surgical instruments across video frames. ShEn score for the instrument sequence was calculated from each surgical trial. Logistic regression using ShEn was used to predict hemorrhage control success. RESULTS: ShEn scores and instrument usage patterns differed between successful and unsuccessful trials (ShEn: 0.452 vs 0.370, P < .001). Unsuccessful hemorrhage control trials displayed lower entropy and less varied instrument use patterns. By contrast, successful trials demonstrated higher entropy with more diverse instrument usage and consistent progression in instrument utilization. A logistic regression model using ShEn scores (78% accuracy and 97% average precision) was at least as accurate as surgeons' attending/resident status and years of experience for predicting trial success and had similar accuracy as expert human observers. CONCLUSION: ShEn score offers a summative signal about surgeon performance and predicted success at controlling carotid hemorrhage in a simulated cadaveric setting. Future efforts to generalize ShEn to additional surgical scenarios can further validate this metric.
- 30 June 2023
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 93 (3) , e81-e82
In Reply: Deep Neural Networks Can Accurately Detect Blood Loss and Hemorrhage Control Task Success from Video
- 30 June 2023
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 93 (3) , e81-e82
In Reply: Deep Neural Networks Can Accurately Detect Blood Loss and Hemorrhage Control Task Success from Video
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape